Jazz will prioritize ABS-1230 development and integrate Actio’s team while the spinout pursues other rare neurology assets.
The acquisition extends Jazz’s rare-epilepsy franchise beyond Epidiolex and signals continued premium pricing for de-risked rare-disease assets with regulatory designations.
AI reasoning
The acquisition extends Jazz’s rare-epilepsy franchise beyond Epidiolex and signals continued premium pricing for de-risked rare-disease assets with regulatory designations.
Curated summary
Jazz Pharmaceuticals agreed to acquire privately held Actio Biosciences for $820 million upfront plus up to $500 million in milestones, centered on ABS-1230 for a rare, severe form of pediatric epilepsy with no FDA-approved treatments, according to Pharmaceutical Executive. Jazz expects the acquisition to close by the fourth quarter of 2026. Actio will spin out a separate rare-neurology company at closing, with Jazz retaining a minority stake; an early pediatric study showed meaningful seizure reductions and the drug holds Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Supporting evidence
YouTube·KinaraBuilding a First-Tier Pharma Culture: A Conversation with Bruce Cozadd, CEO of Jazz Pharmaceuticals
361 engagements5h ago
YouTube·Keck Graduate InstituteSummer Speaker Series - Kevan O’Connor from Jazz Pharmaceuticals
90 engagements5h ago
YouTube·CNBC TelevisionJim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 billion
5h ago
YouTube·CNBC TelevisionJazz Pharmaceuticals buys GW Pharma for $7.2 billion
5h ago
Source news
Jazz Pharmaceuticals to buy Actio Biosciences, betting on rare pediatric epilepsy drug ABS-1230
The deal is built around a first-in-class oral therapy with Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
